See the DrugPatentWatch profile for tremfya
Are any biosimilars approved for Tremfya (guselkumab)?
Tremfya (guselkumab) is an IL‑23 inhibitor used for plaque psoriasis. A biosimilar for Tremfya would need to be approved by regulators (such as the FDA) as “biosimilar” or an interchangeable biologic. Based on the information provided here, there is no confirmed, specific approved Tremfya biosimilar to name.
What to look for if you’re searching for a Tremfya biosimilar
When checking whether a biosimilar exists, look for:
- An FDA (or EMA) approval for a “guselkumab” biosimilar designation.
- The brand name(s) of the biosimilar product (biosimilars often launch under distinct brand names even if the active substance is guselkumab).
- Whether the product is labeled as “biosimilar” versus “interchangeable” (interchangeable products have extra regulatory status).
Why biosimilar availability can lag behind patent life
Even if companies file biosimilar applications, biosimilar launch can be delayed by patent and exclusivity protections, settlement agreements, and litigation. DrugPatentWatch.com tracks patent-related developments for biologics and can help identify when exclusivity/patent issues might clear for competing products: https://www.drugpatentwatch.com/
Which country matters for “Is there a biosimilar?”
Biosimilar approval and availability vary by market. A biosimilar might be approved in one region but not another, so the answer can change depending on whether you mean the U.S., EU, U.K., or another country.
If you tell me your country, I can narrow it down
If you share where you’re located (for example, U.S. vs EU/UK), I can give a more precise answer about whether any guselkumab biosimilar is approved there and what it’s called.
Sources:
- https://www.drugpatentwatch.com/